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Drug-induced autoimmunity is an intriguing phenomenon that has been described in the 
medical literature at least since 1945, with a report from the Medical Corps of the Army 
of the United States describing a case of systemic lupus erythematosus induced by 
sulfadiazine (1). While an autoantibody response in drug-induced autoimmunity is more 
universal, the spectrum of clinical autoimmunity is variable and likely influenced by host 
genetics including genetic variants predisposing to autoimmunity and genetic variants 
affecting drug metabolism. Indeed, a large proportion of patients who take procainamide 
or hydralazine develop autoantibodies, but a smaller fraction develops clinical drug-
induced autoimmunity, usually characterized by skin involvement, arthritis, serositis, and 
constitutional symptoms. In some patients, however, a chronic or severe autoimmune 
disease can develop.    
The identification and withdrawal of the offending drug results in abrogation of drug-
induced autoimmunity in the majority of cases. Nonetheless, understanding the 
mechanisms of drug-induced autoimmunity is important as it can help us better 
understand the pathogenesis of idiopathic autoimmunity. In a pathogenesis paradigm 
that includes a complex etiology involving interaction between genetic predisposition 
and environmental exposures, such as in the case of lupus or vasculitis, drug-induced 
autoimmunity provides a disease model where the extrinsic environmental disease 
trigger is well defined.  
Hydralazine and procainamide are two drugs known to be associated with high risk of 
drug-induced autoimmunity. Work done by Bruce Richardson’s group found that both 
drugs inhibit DNA methylation in T cells (2), and that adoptive transfer of hydralazine or 
procainamide treated CD4+ T cells into mice can cause a lupus-like phenotype (3, 4). 
The same group demonstrated that procainamide directly inhibits the activity of DNA 
methyltransferase 1 (DNMT1) in T cells, while hydralazine inhibits the extracellular-
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expression (5, 6). These critical early observations in drug-induced lupus led to 
exploring T cell DNA methylation defects in idiopathic lupus, resulting in establishing 
epigenetic dysregulation and T cell DNA demethylation as a cornerstone in the 
pathogenesis of this disease (7).  
In the last few years, the role of innate immune response in the pathogenesis of 
autoimmune diseases has been increasingly recognized. Neutrophils constitute the 
majority of peripheral blood while blood cells and their involvement in lupus has been 
suspected at least since the initial description of the Lupus Erythematosus (LE) cell 
phenomenon (neutrophils phagocytosing a whole nucleus or an apoptotic body). 
Neutrophils might also be capable of producing type I interferons in lupus (particularly 
interferon alpha), which plays a key role in the pathogenesis of lupus and other 
autoimmune diseases (8, 9). In addition, the production of anti-neutrophil cytoplasmic 
antibodies (ANCA) is the hallmark of ANCA-associated vasculitis. Following the 
description of a unique neutrophil cell death process involving the formation of 
neutrophil extracellular traps (NETs), called NETosis, studying the role of neutrophils in 
autoimmunity has received special attention. During NETosis dying neutrophils form 
NETs to trap, hinder, and defend against invading pathogens. A genetic defect in NET 
formation, resulting from a predicted deleterious mutation in the neutrophil elastase 
gene ELANE, has been recently reported in a patient with recurrent parvovirus infection 
associated with chronic inflammatory arthritis (10). NETosis involves the release of 
autoantigen-rich nuclear material and granular proteins, and is a process dependent 
upon nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity providing 
reactive oxygen species, and peptidyl arginine deiminase (PAD) 4 catalyzed histone 
citrullination which allows for histone unfolding and chromatin externalization. Deficiency 
in either NADPH oxidase or PAD4 activity is associated with inability of neutrophils to 
undergo NETosis (11, 12). Neutrophils in lupus and ANCA-associated vasculitis 
patients are characterized by an increased tendency for NETosis and reduced NETs 
degradation, resulting in increased and prolonged exposure to autoantigens expelled 
within NETs (13). NETs have been shown to stimulate the production of interferon-alpha 
from plasmacytoid dendritic cells in a Toll-like receptor 9 (TLR9) dependent process 
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extruded within NETs has been recently shown to be a potent interferogenic DNA 
enhancing neutrophil-dependent type I interferon production in lupus (16-18). Type I 
interferons also induce NETosis, and autoantibodies particularly against 
ribonucleoprotein antigens, ANCA, and antiphospholipid antibodies have been 
demonstrated to stimulate NETosis (13). NETs have been described in vasculitic 
lesions in ANCA-associated vasculitis, and renal and skin tissue from lupus patients 
(19, 20). Recent data also suggest that venous thrombosis in an antiphospholipid 
syndrome mouse model is NETosis-dependent (21).  
Irizarry-Caro and colleagues in this issue of Arthritis & Rheumatology demonstrate that 
hydralazine and procainamide can induce NETosis in vitro in neutrophils isolated from 
healthy donors (insert A&R paper to be published reference). These findings suggest a 
mechanism for drug-induced autoimmunity involving the innate immune response. 
Unlike what has been reported in neutrophils isolated from lupus or ANCA-associated 
vasculitis patients, in vitro treatment of healthy neutrophils with hydralazine or 
procainamide did not impair NET degradation. They show that NET formation induced 
by both drugs is dependent upon the formation of reactive oxygen species, as NET 
formation was inhibited with exposure to diphenyleneiodonium chloride, which inhibits 
neutrophil NADPH oxidase and thereby the generation of reactive oxygen species. 
Similarly, NET formation was inhibited with a PAD inhibitor, suggesting that hydralazine 
and procainamide induced NETosis is PAD dependent. Further, they demonstrate that 
hydralazine increases intracellular calcium levels, and that blocking intracellular calcium 
release inhibited hydralazine-induced NET formation. Procainamide did not significantly 
alter intracellular calcium concentrations. Unlike hydralazine, procainamide-induced 
NETosis was inhibited by the muscarinic receptor antagonist atropine and by M1 and 
M3 specific muscarinic receptor antagonists. These observations provide potential 
mechanisms for hydralazine and procainamide induced NETosis. Increase in 
intracellular calcium concentrations and stimulation of muscarinic receptors have been 
both shown to induce NETosis (22, 23). Irizarry-Caro and colleagues also demonstrate 
possible slight differences in the content of NETs induced by hydralazine and 
procainamide, probably reflecting the observed differences in the mechanisms 
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associated with drug-induced autoimmunity, minocycline and clozapine, did not induce 
NETosis.      
The work by Irizarry-Caro and colleagues implicates a possible role for the innate 
immune system in drug-induced autoimmunity. The findings suggest a novel role for 
neutrophils in hydralazine and procainamide-induced autoimmunity, expanding their 
possible pathogenic mechanism beyond their role as T cell DNA methylation inhibitors 
(Figure 1). It is also possible that both mechanisms act synergistically. Increased 
NETosis provides a source of autoantigens, and demethylated T cells induced by these 
drugs are characterized by increased capacity for autoreactivity, inducing B cell co-
stimulation and an autoimmune response (Figure 1). Future studies performed on 
neutrophils isolated from patients with drug-induced autoimmunity will help to confirm 
the role of enhanced NETosis in hydralazine and procainamide induced autoimmunity. 
To prove a causal relationship, animal studies using hydralazine and procainamide 
treated neutrophils will be needed, with the realization that neutrophil short half-life will 
be a limitation. Integrating the findings of this report with previously known mechanisms 
for drug-induced autoimmunity will be important to consider in future studies.  For 
example, as mentioned above, hydralazine inhibits ERK signaling in T cells resulting in 
reduced expression of DNMT1, while procainamide directly inhibits DNMT1. Previous 
work suggested that ERK signaling is activated during NETosis, and that inhibiting ERK 
signaling inhibits NET formation (24). Is it possible that increased intracellular calcium 
induced by hydralazine by-passes any possible effect of hydralazine on neutrophil ERK 
signaling? Or perhaps hydralazine does not affect ERK signaling in neutrophils? Or is it 
possible that both increased and decreased ERK signaling can induce NETosis utilizing 
different mechanisms that might or might not involve changes in intracellular calcium 
concentrations, as multiple diverse pathways have been recently shown to induce 
NETosis? Lupus neutrophils are demethylated compared to neutrophils from healthy 
matched controls (25). Procainamide is a DNA methylation inhibitor, so does inhibiting 
DNA methylation in neutrophils by procainamide or other DNA methylation inhibitors 
contribute to enhanced NETosis? It is also tempting to explore the possibility that 
hydralazine and procainamide both inhibit neutrophil DNA methylation in addition to 
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the same time enhancing the immunogenic and interferogenic properties of released 
NETs through an augmented TLR9 stimulation, as TLR9 is sensitive to demethylated 
DNA (Figure 1).  
 
There is an important contrast that can be realized between the initial work implicating 
DNA demethylation in T cells (adaptive immunity) and the current work implicating 
increased NETosis (innate immunity) in drug-induced autoimmunity. In the former, the 
implicated mechanism (T cell DNA demethylation) was first described and characterized 
in drug-induced autoimmunity and then extended to help understand idiopathic 
autoimmunity, while in the latter a role for NETosis was initially described in  idiopathic 
autoimmunity. In both cases, however, drug-induced autoimmunity provides an 
excellent disease model to further understand idiopathic disease. Additional exploration 
and characterization of drug-induced NETosis and the autoantigen ‘cargo’ carried within 
released NETs will help us better understand autoimmune mechanisms. Whether other 
environmental triggers either previously known to be involved in autoimmunity (such as 
Epstein-Barr virus infection) or triggers yet to be discovered can contribute to disease 
pathogenesis, progression, or flares via mechanisms resulting in increased NETosis is 
something to be considered. Studies to uncover the diverse mechanisms behind drug-
induced autoimmunity will collectively provide a better understanding of the role of 
environmental triggers in idiopathic autoimmune diseases and potentially identify novel 
therapeutic targets.  
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Figure 1: Drug-induced autoimmunity involves both adaptive and innate immune 
mechanisms. Both procainamide and hydralazine have been previously shown to 
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regulates the expression of DNMT1, while procainamide is a direct inhibitor of DNMT1. 
Both hydralazine and procainamide induce T cell demethylation, T cell autoreactivity in 
vitro, and T cell-mediated autoimmunity in vivo. The present study suggests that both 
drugs can induce NETosis, implicating the innate immune response in drug-induced 
autoimmunity. Hydralazine increases intracellular calcium concentrations, while 
procainamide induced NETosis through stimulation of neutrophil muscarinic receptors 
(particularly M1 and M3 receptors). NETosis is known to stimulate type I interferon 
production from plasmacytoid dendritic cells through TLR9 stimulation, and provides a 
source for autoantigens released within NETs. It remains to be seen if procainamide 
and hydralazine also inhibit DNA methylation in neutrophils, similar to what has been 
described in T cells, and if this might induce neutrophil DNA demethylation, similar to 
what has been described in neutrophils in idiopathic lupus. Demethylated DNA released 
within NETs might result in enhanced TLR9 stimulation, as TLR9 is sensitive to 
demethylated DNA.      
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
art_40371_f1.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
